SCHEMBL23875531

SCHEMBL23875531

c1ccc(N(CCn2cncn2)c2ccc3[nH]c4ccccc4c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ LMNA P02545 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP19A1 P11511 5/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ HTT P42858 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HSP90AA1 P07900 1/20 0.35
▸ TP53 P04637 3/20 0.35
▸ TSHR P16473 1/20 0.35
▸ AHR P35869 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30058010 1.00 EGLN3 (0.41) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL23875552 0.87 MAPT (0.40) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL25783490 0.83 FGFR1 (0.38) KDM4EALDH1A1AHRTDP1SLC6A2
SCHEMBL23875574 0.80 LMNA (0.39) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL23875556 0.70 SMN1; SMN2 (0.41) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL30059669 0.68 EGLN3 (0.44) EGLN3KDM4EMAPTCYP19A1SMN1; SMN2
SCHEMBL23875666 0.68 EGLN3 (0.44) EGLN3KDM4EMAPTCYP19A1SMN1; SMN2
SCHEMBL23876020 0.68 CYP19A1 (0.49) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL25792508 0.67 EGLN3 (0.47) EGLN3KDM4EMAPTLMNAMEN1
SCHEMBL1689481 0.67 AHR (0.55) KDM4EMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed
CN-115335046-A Lipoxygenase inhibitors 思研(SRI)国际顾问与咨询公司 2022-11-11 — — CN disclosed
WO-2021195346-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 EGLN3 752/4885KDM4E 1282/4885MAPT 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback